Although not used in acute treatment, it has been hypothesized that glucagon-like peptide-1 receptor agonists (GLP-1RA) can aid in heart failure (HF) management in post-MI patients by improving glucose uptake, promoting the release of guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP), ultimately enhancing coronary flow and cardiac function [4]. Here, GLP1R is linked to myocardial infarction.